TScan Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 5, 2025
TCRX$0.18-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $178,689 | $133,359 |
| Marketable securities | 111,421 | 58,685 |
| Prepaid expenses and other current assets | 2,612 | 2,193 |
| Total current assets | 292,722 | 194,237 |
| Property and equipment, net | 7,242 | 7,742 |
| Right-of-use assets | 64,357 | 63,492 |
| Restricted cash | 5,031 | 5,031 |
| Long-term deposit and other assets | 1,766 | 1,647 |
| Total assets | $371,118 | $272,149 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,278 | $2,374 |
| Accrued expenses and other current liabilities | 15,410 | 10,716 |
| Operating lease liability, current portion | 4,570 | 3,246 |
| Deferred revenue, current portion | 11,698 | 10,137 |
| Current portion of long-term debt | - | 3,347 |
| Total current liabilities | 35,956 | 29,820 |
| Deferred revenue, net of current portion | 1,246 | 5,622 |
| Operating lease liability, net of current portion | 60,739 | 59,140 |
| Long-term debt and accrued interest | 32,072 | 26,700 |
| Other long term liabilities | 135 | - |
| Total liabilities | 130,148 | 121,282 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Preferred Stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023 | - | - |
| Voting common stock, $0.0001 par value; 300,000,000 shares authorized; 52,314,039 and 43,552,941 shares issued and outstanding at December 31, 2024 and 2023, respectively | 5 | 4 |
| Non-voting common stock, $0.0001 par value; 10,000,000 shares authorized; 4,276,588 shares issued and outstanding at December 31, 2024 and 2023 | 1 | 1 |
| Additional paid-in capital | 616,009 | 398,459 |
| Accumulated other comprehensive income | 51 | - |
| Accumulated deficit | (375,096) | (247,597) |
| Total stockholders' equity | 240,970 | 150,867 |
| Total liabilities and stockholders' equity | $371,118 | $272,149 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.